Xinjiang Tumor Hospital

Urunchi, China

Xinjiang Tumor Hospital

Urunchi, China
SEARCH FILTERS
Time filter
Source Type

Meng F.-F.,Xinjiang Tumor Hospital | Xu Y.,University of Sichuan | Dan Q.-Q.,University of Sichuan | Dan Q.-Q.,Kunming Medical University | And 10 more authors.
Cancer Science | Year: 2015

Bone cancer pain is a common symptom in cancer patients with bone metastases and the underlying mechanisms are largely unknown. The aim of this study is to explore the endogenous analgesic mechanisms to develop new therapeutic strategies for bone-cancer induced pain (BCIP) as a result of metastases. MRMT-1 tumor cells were injected into bilateral tibia of rats and X-rays showed that the area suffered from bone destruction, accompanied by an increase in osteoclast numbers. In addition, rats with bone cancer showed apparent mechanical and thermal hyperalgesia at day 28 after intratibial MRMT-1 inoculation. However, intrathecal injection of morphine or lentivirus-mediated glial cell line-derived neurotrophic factor RNAi (Lvs-siGDNF) significantly attenuated mechanical and thermal hyperalgesia, as shown by increases in paw withdrawal thresholds and tail-flick latencies, respectively. Furthermore, Lvs-siGDNF interference not only substantially downregulated GDNF protein levels, but also reduced substance P immunoreactivity and downregulated the ratio of pERK/ERK, where its activation is crucial for pain signaling, in the spinal dorsal horn of this model of bone-cancer induced pain. In this study, Lvs-siGDNF gene therapy appeared to be a beneficial method for the treatment of bone cancer pain. As the effect of Lvs-siGDNF to relieve pain was similar to morphine, but it is not a narcotic, the use of GDNF RNA interference may be considered as a new therapeutic strategy for the treatment of bone cancer pain in the future. © 2015 The Authors. Cancer Science published by Wiley Publishing Asia Pty Ltd on behalf of Japanese Cancer Association.


Feng X.,Chongqing Medical University | Xu R.,Hunan Provincial Tumor Hospital | Du X.,PLA Fourth Military Medical University | Dou K.,Xijing University | And 9 more authors.
American Journal of Gastroenterology | Year: 2014

OBJECTIVES:The objective of this study was to evaluate the efficacy of combined therapy using Sorafenib and radiofrequency ablation (RFA) with curative intent for all detectable lesions in patients with Barcelona Clinic Liver Cancer (BCLC) Stage 0-B1 hepatocellular carcinoma (HCC).METHODS:One hundred and twenty-eight patients with HCC from 12 centers were enrolled in this retrospective study; 64 patients who received Sorafenib plus RFA (Sorafenib-RFA) were compared with a control group treated with RFA alone. The two patient groups were selected with a predefined criterion and matched in terms of their clinical and tumor characteristics at baseline. The primary end point of the study was the incidence of post-RFA HCC recurrence. Secondary end points were overall survival (OS) and treatment toxicity.RESULTS:During a median follow-up of 134.1 weeks, 49 patients died and 79 survived. The 1-, 2-, and 3-year cumulative incidences of post-RFA recurrence were 40.5%, 62.9%, and 74.5%, respectively, in the Sorafenib-RFA group, and 62.8%, 85.4%, and 92.7%, respectively, in the RFA group. The 1-, 2-, 3-, and 4-year OS rates were 85.6%, 64.0%, 58.7%, and 50.3%, respectively, in the Sorafenib-RFA group, and 80.7%, 47.2%, 30.9%, and 30.9%, respectively, in the RFA group. Thus, the Sorafenib-RFA group exhibited better survival than the RFA alone group.CONCLUSIONS:Combined therapy with Sorafenib-RFA was associated with a lower incidence of post-RFA recurrence and better OS than RFA alone in patients with BCLC Stage 0-B1 HCC. Although these findings suggest that Sorafenib and RFA is safe and effective for the treatment of early HCC, prospective and randomized controlled trials are needed to validate them. © 2014 by the American College of Gastroenterology.


PubMed | Xinjiang Tumor Hospital, Tangdu Hospital of Forth Military Medical University, Henan Cancer Hospital, Xijing University and 7 more.
Type: Journal Article | Journal: The American journal of gastroenterology | Year: 2014

The objective of this study was to evaluate the efficacy of combined therapy using Sorafenib and radiofrequency ablation (RFA) with curative intent for all detectable lesions in patients with Barcelona Clinic Liver Cancer (BCLC) Stage 0-B1 hepatocellular carcinoma (HCC).One hundred and twenty-eight patients with HCC from 12 centers were enrolled in this retrospective study; 64 patients who received Sorafenib plus RFA (Sorafenib-RFA) were compared with a control group treated with RFA alone. The two patient groups were selected with a predefined criterion and matched in terms of their clinical and tumor characteristics at baseline. The primary end point of the study was the incidence of post-RFA HCC recurrence. Secondary end points were overall survival (OS) and treatment toxicity.During a median follow-up of 134.1 weeks, 49 patients died and 79 survived. The 1-, 2-, and 3-year cumulative incidences of post-RFA recurrence were 40.5%, 62.9%, and 74.5%, respectively, in the Sorafenib-RFA group, and 62.8%, 85.4%, and 92.7%, respectively, in the RFA group. The 1-, 2-, 3-, and 4-year OS rates were 85.6%, 64.0%, 58.7%, and 50.3%, respectively, in the Sorafenib-RFA group, and 80.7%, 47.2%, 30.9%, and 30.9%, respectively, in the RFA group. Thus, the Sorafenib-RFA group exhibited better survival than the RFA alone group.Combined therapy with Sorafenib-RFA was associated with a lower incidence of post-RFA recurrence and better OS than RFA alone in patients with BCLC Stage 0-B1 HCC. Although these findings suggest that Sorafenib and RFA is safe and effective for the treatment of early HCC, prospective and randomized controlled trials are needed to validate them.


Zhu M.-Y.,Xinjiang Medical University | Chen F.,General Hospital of Xinjiang Military Area Command | Niyazi M.,Autonomous Region Peoples Hospital in Xin Jiang | Sui S.,Xinjiang Medical University | Gao D.-M.,Xinjiang Tumor Hospital
Journal of Lower Genital Tract Disease | Year: 2015

OBJECTIVE: The current study aimed to investigate the molecular basis of cervical cancer development using a microarray to identify the differentially expressed genes. This study also aimed to detect apoptosis genes and proteins to find those genes most aberrantly expressed in cervical cancer and to explore the cause of Uighur cervical cancer.METHODS: An analysis of gene expression profiles obtained from cervical cancer cases was performed. Total RNA was prepared from 10 samples of cervical carcinoma and normal cervix and was hybridized to Affymetrix oligonucleotide microarrays with probe sets complementary to more than 20,000 transcripts. Several genes of the apoptosis pathway, which were differentially regulated, included BCL2, BCLXL, and c-IAP1. These were validated by quantitative reverse transcription-polymerase chain reaction and immunohistochemical staining on an independent set of cancer and control specimens.RESULTS: Unsupervised hierarchical clustering of the expression data readily distinguished the normal cervix from cancer. Supervised analysis of gene expression data identified 1,326 and 1,432 genes that were upregulated and downregulated, respectively; a set of genes belonging to the apoptosis pathways were upregulated or downregulated in patients with cervical cancer. BCL2, BCLXL, and c-IAP1 were found to be upregulated in late-stage cancer compared to early-stage cancer.CONCLUSIONS: These findings provide a new understanding of the gene expression profile in cervical cancer. BCL2, BCLXL, and c-IAP1 might be involved in cancer progression. The pathway analysis of expression data showed that the BCL2, BCLXL, and c-IAP1 genes were coordinately differentially regulated between cancer and normal cases. Our results may serve as basis for further development of biomarkers for the diagnosis and treatment of cervical cancer. © 2014, American Society for Colposcopy and Cervical Pathology.


Zheng X.,Xi'an Jiaotong University | Gai X.,Xi'an Jiaotong University | Wu Z.,Xinjiang Tumor Hospital | Liu Q.,Xi'an Jiaotong University | Yao Y.,Xi'an Jiaotong University
Oncology Reports | Year: 2013

Hepatocellular carcinoma (HCC) is a common malignant cancer worldwide characterized by high metastatic potential and poor prognosis following radical resection. Metastasin is a Ca2+-binding protein associated with tumor metastasis. However, the expression and function of metastasin remain unknown. In the present study, we found that the expression of metastasin was upregulated in HCC tissues and positively correlated with poor prognosis following radical resection. Ectopic expression of metastasin in vitro induced typical epithelial-mesenchymal transition (EMT) in Hep3B cells including higher capacity of both migration and invasion, increased expression of both Vimentin and N-cadherin and decreased expression of E-cadherin. Knockdown of metastasin produced the opposite results in MHCC97H cells, which indicates that metastasin promotes HCC progression via induction of EMT. SNAI1 expression was upregulated by enforced expression of metastasin and, consequently, suppressing upregulation of SNAI1 secondary to metastasin overexpression abolished EMT. Collectively, the present results suggest that metastasin leads to HCC EMT partly through upregulating SNAI1 and contributes to poor prognosis following radical liver resection.


A-You-Fu A.-S.-K.-E.,Xinjiang Tumor Hospital | Tu-Er-Hong A.-D.-L.,Xinjiang Tumor Hospital | Sha-Lie-Er T.-L.-H.,Xinjiang Tumor Hospital | Ou J.-H.,Xinjiang Tumor Hospital | Xian-Mu-Xi-Ding Y.-L.-X.-T.,Xinjiang Tumor Hospital
Chinese Journal of Cancer Prevention and Treatment | Year: 2016

OBJECTIVE: To study the genotype distribution of cytochrome P450CYP2C19 and CYP2D6 in Han and Uyghur women with breast cancer in Xinjiang, compared with the both Han and Uyghur in genetic frequency as well as the metabolism type for clinical. METHODS: CYP2C19, CYP2D6 genotypes were tested by TaqMan®R-MGB method and the metabolism type of tamoxifen was conformed in the 246 premenopausal hormone reactive women breast cancer patients (125 Han and 121 Uyghur) who used or were about to use Tamoxifen for endocrine therapy. RESULTS: In selected patients, the CYP2D6 (*1/*1), CYP2D6 (*10/*10) and CYP2C19 (*1/*1) genotypes showed obvious difference in two groups (P=0.029, P=0.002, P=0.015), and there were no expressions of CYP2D6 (*1/*5), CYP2D6 (*5/*5), CYP2D6 (*5/*10), CYP2C19 (*3/*3) genotypes in two groups (all P>0.05). The CYP2D6 (*1/*1), CYP2C19(*1/*2), CYP2C19 (*2/*2), CYP2C19 (*1/*3) and CYP2C19 (*2/*3) genotypes showed no significant difference in the two groups (all P>0.05). The ratio of extensive, intermediate and poor Metabolism type were respectively 72.0%, 24.0%, 4.0% and 76.9%, 17.4%, 5.7% in two groups (P>0.05). CONCLUSIONS: The genotypes of CYP2C19*2, CYP2C19*3 have no significant racial differences in both Han and Uyghur premenopausal women with breast cancer patients, and the CYP2D6*10 allele frequency in Uighur groups relative to the Han group demonstrates significant racial difference. The metabolism type of tamoxifen in two groups has no significant racial differences and both are dominated by a extensive metabolism type. © 2016, Editorial Board of Chinese Journal of Cancer Prevention and Treatment. All right reserved.


Xue S.P.,Xinjiang Tumor Hospital | Yu T.T.,Xinjiang Tumor Hospital | Zhang Y.,Xinjiang Tumor Hospital | Shan L.,Xinjiang Tumor Hospital
Chinese Journal of Lung Cancer | Year: 2015

In recent years, the chemotherapy of non-small cell lung cancer (NSCLC) has almost been reached a platform stage, and there is no obvious progress in terms of response rate (RR) and overall survival (OS); With the great development of molecular biology, epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) has good therapeutic effect on the NSCLC. But, almost all patients of EGFR-mutant lung cancers develop drug resistance to these agents. This paper reported a case of a 49-year-old woman with lung adenocarcinoma who had EGFR mutant (19-DEL) treated with EGFR-TKIs. After disease progression, histological examination of a secondary biopsy specimen revealed small cell lung cancer (SCLC) had transformed to SCLC treatment. Through the analysis of the process and effect of her therapy, the following is a summary of the relevant mechanism. © 2015, Chinese Journal of Lung Cancer. All Rights Reserved.


PubMed | Xinjiang Tumor Hospital
Type: Case Reports | Journal: Zhongguo fei ai za zhi = Chinese journal of lung cancer | Year: 2015

In recent years, the chemotherapy of non-small cell lung cancer (NSCLC) has almost been reached a platform stage, and there is no obvious progress in terms of response rate (RR) and overall survival (OS); With the great development of molecular biology, epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) has good therapeutic effect on the NSCLC. But, almost all patients of EGFR-mutant lung cancers develop drug resistance to these agents. This paper reported a case of a 49-year-old woman with lung adenocarcinoma who had EGFR mutant (19-DEL) treated with EGFR-TKIs. After disease progression, histological examination of a secondary biopsy specimen revealed small cell lung cancer (SCLC) had transformed to SCLC treatment. Through the analysis of the process and effect of her therapy, the following is a summary of the relevant mechanism.

Loading Xinjiang Tumor Hospital collaborators
Loading Xinjiang Tumor Hospital collaborators